Hepatoprotective Effect of SGLT2 Inhibitor on Nonalcoholic Fatty Liver Disease-Reference-Cited by-同舟云学术

Hepatoprotective Effect of SGLT2 Inhibitor on Nonalcoholic Fatty Liver Disease

Published:2020-03-05 Issue:S1 Volume:2 Page:17-25
ISSN:
Container-title:SGLT2 inhibitors
language:en
Short-container-title:Diab Res Open Access

Author:

Y Sumida¹,M Yoneda¹,K Tokushige²,M Kawanaka³,H Fujii⁴,M Yoneda⁵,K Imajo⁵,H Takahashi⁶,M Ono⁷,Y Nozaki⁸,H Hyogo⁹,M Koseki¹⁰,Y Yoshida¹¹,T Kawaguchi¹²,Y Kamada¹³,Y Eguchi¹⁴,T Okanoue¹⁵,A Nakajima⁵

Affiliation:

1. Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University, Japan

2. Department of Internal Medicine, Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo, Japan

3. Department of General Internal Medicine2, Kawasaki Medical School, Okayama 700-8505, Japan

4. Department of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, Japan

5. Division of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

6. Department of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga, Japan

7. Division of Gastroenterology and Hepatology, Department of Internal Medicine,Tokyo Women’s Medical University Medical Center East, Tokyo, Japan

8. Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan

9. Department of Gastroenterology, JA Hiroshima General Hospital, Japan

10. Department of Cardiovascular Medicine, Department of Medicine, Osaka University Graduate School of Medicine

11. Department of Gastroenterology and Hepatology, Suita Municipal Hospital, Osaka, Japan

12. Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan

13. Department of Molecular Biochemistry & Clinical Investigation, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

14. Liver Center, Saga University Hospital, Saga, Japan

15. Hepatology Center, Saiseikai Suita Hospital, Osaka, Japan

Abstract

A fourth of the adult population is now suffering from nonalcoholic fatty liver disease (NAFLD) worldwide. Nonalcoholic steatohepatitis (NASH), a severe form of NAFLD, can lead to liver-related mortality. NAFLD/NASH is closely associated with type 2 diabetes. Although pioglitazone is now recommended as the 1st line therapy for NASH with type 2 diabetes, pioglitazone has several safety concerns such as body weight gain, heart failure, fluid retention, and bone fracture in women. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have a variety of functions such as glycemic control, bodyweight reduction, and decreased body pressure. Accumulating evidence has shown that this agent has also cardioprotective and renoprotective effects in patients with or without type 2 diabetes. Recent studies that SGLT2 inhibitor can also reduce in transaminase activities or hepatic fat content in NAFLD. NAFLD patients with type 2 diabetes can be indicated for SGLT2 inhibitor, because they are obese, have insulin resistance, and at high risk of cardiovascular events. The phase 3 study of dapagliflozin for NAFLD (DEAN study) is now ongoing. It remains unknown whether this agent can ameliorate hepatic fibrosis in NASH, leading to improved over-all or liver-related survival. Since the leading cause of NAFLD mortality is cardiovascular events, SGLT2 inhibitors will become the 1st line treatment for NAFLD/NASH.

Publisher

Asploro Open Access Publications

Reference21 articles.

1. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-306. [PMID: 30990260]

2. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. [PMID: 31535829]

3. Shima T, Uto H, Ueki K, Kohgo Y, Yasui K, Nakamura N, Nakatou T, Takamura T, Kawata S, Notsumata K, Sakai K, Tateishi R, Okanoue T. Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients. J Gastroenterol. 2019 Jan;54(1):64-77. [PMID: 30006904]

4. Nakahara T, Hyogo H, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Ono M, Kawaguchi T, Imajo K, Aikata H, Tanaka S, Kanemasa K, Fujimoto K, Anzai K, Saibara T, Sata M, Nakajima A, Itoh Y, Chayama K, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. 2014 Nov;49(11):1477-84. [PMID: 24277052]

5. Fujii H, Imajo K, Yoneda M, Nakahara T, Hyogo H, Takahashi H, Hara T, Tanaka S, Sumida Y, Eguchi Y, Chayama K, Nakajima A, Nishimoto N, Kawada N; Japan Study Group of Nonalcoholic Fatty Liver Disease. HOMA-IR: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2019 Aug;34(8):1390-95. [PMID: 30600551]

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Empagliflozin on Hepatotoxicity Induced by Cyclophosphamide in Male Rats;Armaghane Danesh;2024-03-01

2. Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond;Biomedicines;2024-02-08

3. Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD);Diabetes Obesity Metabolic Syndrome;2023-10-27

4. Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates;Biomedicines;2022-01-26

5. Efficacy and Cardiovascular Safety of SGLT2 Inhibitors;Current Drug Safety;2021-06-08